中国儿童银屑病诊疗专家共识(2021)

Consensus on the diagnosis and treatment of childhood psoriasis in China(2021)

儿童银屑病是一种发生于儿童(年龄<18岁)、由遗传和环境因素(如感染等)共同作用诱发的慢性、复发性、免疫性、系统性皮肤病。儿童银屑病临床表现复杂,型别差异大。因儿童的特殊生理特点,在治疗方面更应注重安全性。相对于成人,儿童银屑病的治疗方法较局限且具有挑战性,如系统药物的理想治疗剂量、长期治疗产生的不良反应、联合用药的选择、药物的转换等尚未明确。许多药物,包括局部药物和系统药物未被批准用于治疗儿童银屑病。建立儿童银屑病诊疗共识的目的是更加有效、科学地规范儿童银屑病诊疗管理,指导医师及时、有效地控制儿童银屑病发生与发展,改善和提高患儿及家庭生活质量,帮助患儿尽可能健康地发育和成长。

Childhood psoriasis is an immune-mediated chronic,recurrent,systemic skin disease induced by both genetic and environmental factors(e.g.,infection,etc.)and occurring in children aged under 18 years.Its clinical manifestations are complex and vary widely between different types.Because of the special physiological condition of children,more attention should be paid to safety of treatment.Compared with adults,the treatment of psoriasis in children is more challenging due to limited options.For example,the ideal therapeutic dose of systemic drugs,adverse effects of long-term treatment,the choice of drug combination,and the conversion of drugs have not been clarified.Many drugs,including topical and systemic drugs,have not been approved for the treatment of childhood psoriasis.The purpose of this consensus is to standardize the diagnosis and treatment of childhood psoriasis more effectively and scientifically,to guide physicians to timely and effective control of occurrence and development of childhood psoriasis,to improve the quality of life of children and their families,and to help children develop and grow as healthily as possible.